Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE) - Trial NCT00317681
Access comprehensive clinical trial information for NCT00317681 through Pure Global AI's free database. This Phase 2 trial is sponsored by Heinrich-Heine University, Duesseldorf and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Heinrich-Heine University, Duesseldorf
Timeline & Enrollment
Phase 2
Aug 01, 2005
Feb 01, 2007
Primary Outcome
Difference in skin lesions of patients with CLE before (begin of study) and after treatment (end of study) evaluated by a clinical score
Summary
The purpose of this study is to evaluate the efficacy of topical tacrolimus in different
 subtypes of cutaneous lupus erythematosus. As shown by several groups activated memory T
 lymphocytes play a key role in the pathogenesis of lupus erythematosus. Tacrolimus targets T
 lymphocytes and suppresses their activation by inhibiting the expression of cytokine genes,
 such as IL-2. Therefore, treatment of cutaneous lupus erythematosus with topical tacrolimus
 might result in an improvement of skin lesions in such patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT00317681
Non-Device Trial